GRO Biosciences Raises $60.3 Million in Series B Funding for Lead Program and Market Expansion

GRO Biosciences raises $60.3M in Series B Funding

GRO Biosciences (Linkedin), a leader in pharmaceutical manufacturing, recently secured $60.3M in Series B funding, bringing their total funding to over $90M. They are focused on developing therapeutics for severe, refractory gout, a debilitating form of arthritis caused by excessive uric acid accumulation.

Funding Amount: $60.3 million

Industry: Pharmaceutical Manufacturing

Employee Count: 11-50

CEO: Dan Mandell (CEO Linkedin)

What GRO Biosciences needs to buy: GRO Biosciences is seeking partnerships with clinical research organizations, manufacturers, suppliers, and regulatory experts to advance their lead program, expand their pipeline, and ensure compliance in the development and commercialization of their therapeutics. Biotechnology and pharmaceutical companies, as well as healthcare providers specializing in gout and autoimmune diseases, are ideal partners for GRO Biosciences.